Interferon-Gamma Modification of Mesenchymal Stem Cells: Implications of Autologous and Allogeneic Mesenchymal Stem Cell Therapy in Allotransplantation

Kisha Nandini Sivanathan, Stan Gronthos, Darling Rojas-Canales, Benjamin Thierry, P. Toby Coates

Research output: Contribution to journalArticle

76 Citations (Scopus)

Abstract

Bone marrow-derived mesenchymal stem cells (MSC) have unique immunomodulatory and reparative properties beneficial for allotransplantation cellular therapy. The clinical administration of autologous or allogeneic MSC with immunosuppressive drugs is able to prevent and treat allograft rejection in kidney transplant recipients, thus supporting the immunomodulatory role of MSC. Interferon-gamma (IFN-γ) is known to enhance the immunosuppressive properties of MSC. IFN-γ preactivated MSC (MSC-γ) directly or indirectly modulates T cell responses by enhancing or inducing MSC inhibitory factors. These factors are known to downregulate T cell activation, enhance T cell negative signalling, alter T cells from a proinflammatory to an anti-inflammatory phenotype, interact with antigen-presenting cells and increase or induce regulatory cells. Highly immunosuppressive MSC-γ with increased migratory and reparative capacities may aid tissue repair, prolong allograft survival and induce allotransplant tolerance in experimental models. Nevertheless, there are contradictory in vivo observations related to allogeneic MSC-γ therapy. Many studies report that allogeneic MSC are immunogenic due to their inherent expression of major histocompatibility (MHC) molecules. Enhanced expression of MHC in allogeneic MSC-γ may increase their immunogenicity and this can negatively impact allograft survival. Therefore, strategies to reduce MSC-γ immunogenicity would facilitate "off-the-shelf" MSC therapy to efficiently inhibit alloimmune rejection and promote tissue repair in allotransplantation. In this review, we examine the potential benefits of MSC therapy in the context of allotransplantation. We also discuss the use of autologous and allogeneic MSC and the issues associated with their immunogenicity in vivo, with particular focus on the use of enhanced MSC-γ cellular therapy.

LanguageEnglish
Pages351-375
Number of pages25
JournalStem Cell Reviews and Reports
Volume10
Issue number3
DOIs
Publication statusPublished - 1 Jan 2014

Keywords

  • Allogeneic
  • Allograft rejection
  • Allotransplantation
  • Autologous
  • Cellular therapy
  • Clinical trials
  • Immunogenicity
  • Immunosuppression
  • Immunosuppressive drugs
  • Interferon-gamma
  • Mesenchymal stem cells
  • Modification
  • Monotherapy
  • Preactivation
  • Regeneration
  • T cells

ASJC Scopus subject areas

  • Cell Biology
  • Cancer Research

Cite this

Sivanathan, Kisha Nandini ; Gronthos, Stan ; Rojas-Canales, Darling ; Thierry, Benjamin ; Coates, P. Toby. / Interferon-Gamma Modification of Mesenchymal Stem Cells : Implications of Autologous and Allogeneic Mesenchymal Stem Cell Therapy in Allotransplantation. In: Stem Cell Reviews and Reports. 2014 ; Vol. 10, No. 3. pp. 351-375.
@article{bcd2a3ec776047f0a0ba611a549f9984,
title = "Interferon-Gamma Modification of Mesenchymal Stem Cells: Implications of Autologous and Allogeneic Mesenchymal Stem Cell Therapy in Allotransplantation",
abstract = "Bone marrow-derived mesenchymal stem cells (MSC) have unique immunomodulatory and reparative properties beneficial for allotransplantation cellular therapy. The clinical administration of autologous or allogeneic MSC with immunosuppressive drugs is able to prevent and treat allograft rejection in kidney transplant recipients, thus supporting the immunomodulatory role of MSC. Interferon-gamma (IFN-γ) is known to enhance the immunosuppressive properties of MSC. IFN-γ preactivated MSC (MSC-γ) directly or indirectly modulates T cell responses by enhancing or inducing MSC inhibitory factors. These factors are known to downregulate T cell activation, enhance T cell negative signalling, alter T cells from a proinflammatory to an anti-inflammatory phenotype, interact with antigen-presenting cells and increase or induce regulatory cells. Highly immunosuppressive MSC-γ with increased migratory and reparative capacities may aid tissue repair, prolong allograft survival and induce allotransplant tolerance in experimental models. Nevertheless, there are contradictory in vivo observations related to allogeneic MSC-γ therapy. Many studies report that allogeneic MSC are immunogenic due to their inherent expression of major histocompatibility (MHC) molecules. Enhanced expression of MHC in allogeneic MSC-γ may increase their immunogenicity and this can negatively impact allograft survival. Therefore, strategies to reduce MSC-γ immunogenicity would facilitate {"}off-the-shelf{"} MSC therapy to efficiently inhibit alloimmune rejection and promote tissue repair in allotransplantation. In this review, we examine the potential benefits of MSC therapy in the context of allotransplantation. We also discuss the use of autologous and allogeneic MSC and the issues associated with their immunogenicity in vivo, with particular focus on the use of enhanced MSC-γ cellular therapy.",
keywords = "Allogeneic, Allograft rejection, Allotransplantation, Autologous, Cellular therapy, Clinical trials, Immunogenicity, Immunosuppression, Immunosuppressive drugs, Interferon-gamma, Mesenchymal stem cells, Modification, Monotherapy, Preactivation, Regeneration, T cells",
author = "Sivanathan, {Kisha Nandini} and Stan Gronthos and Darling Rojas-Canales and Benjamin Thierry and Coates, {P. Toby}",
year = "2014",
month = "1",
day = "1",
doi = "10.1007/s12015-014-9495-2",
language = "English",
volume = "10",
pages = "351--375",
journal = "Stem Cell Reviews and Reports",
issn = "1550-8943",
publisher = "Humana Press",
number = "3",

}

Interferon-Gamma Modification of Mesenchymal Stem Cells : Implications of Autologous and Allogeneic Mesenchymal Stem Cell Therapy in Allotransplantation. / Sivanathan, Kisha Nandini; Gronthos, Stan; Rojas-Canales, Darling; Thierry, Benjamin; Coates, P. Toby.

In: Stem Cell Reviews and Reports, Vol. 10, No. 3, 01.01.2014, p. 351-375.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Interferon-Gamma Modification of Mesenchymal Stem Cells

T2 - Stem Cell Reviews and Reports

AU - Sivanathan, Kisha Nandini

AU - Gronthos, Stan

AU - Rojas-Canales, Darling

AU - Thierry, Benjamin

AU - Coates, P. Toby

PY - 2014/1/1

Y1 - 2014/1/1

N2 - Bone marrow-derived mesenchymal stem cells (MSC) have unique immunomodulatory and reparative properties beneficial for allotransplantation cellular therapy. The clinical administration of autologous or allogeneic MSC with immunosuppressive drugs is able to prevent and treat allograft rejection in kidney transplant recipients, thus supporting the immunomodulatory role of MSC. Interferon-gamma (IFN-γ) is known to enhance the immunosuppressive properties of MSC. IFN-γ preactivated MSC (MSC-γ) directly or indirectly modulates T cell responses by enhancing or inducing MSC inhibitory factors. These factors are known to downregulate T cell activation, enhance T cell negative signalling, alter T cells from a proinflammatory to an anti-inflammatory phenotype, interact with antigen-presenting cells and increase or induce regulatory cells. Highly immunosuppressive MSC-γ with increased migratory and reparative capacities may aid tissue repair, prolong allograft survival and induce allotransplant tolerance in experimental models. Nevertheless, there are contradictory in vivo observations related to allogeneic MSC-γ therapy. Many studies report that allogeneic MSC are immunogenic due to their inherent expression of major histocompatibility (MHC) molecules. Enhanced expression of MHC in allogeneic MSC-γ may increase their immunogenicity and this can negatively impact allograft survival. Therefore, strategies to reduce MSC-γ immunogenicity would facilitate "off-the-shelf" MSC therapy to efficiently inhibit alloimmune rejection and promote tissue repair in allotransplantation. In this review, we examine the potential benefits of MSC therapy in the context of allotransplantation. We also discuss the use of autologous and allogeneic MSC and the issues associated with their immunogenicity in vivo, with particular focus on the use of enhanced MSC-γ cellular therapy.

AB - Bone marrow-derived mesenchymal stem cells (MSC) have unique immunomodulatory and reparative properties beneficial for allotransplantation cellular therapy. The clinical administration of autologous or allogeneic MSC with immunosuppressive drugs is able to prevent and treat allograft rejection in kidney transplant recipients, thus supporting the immunomodulatory role of MSC. Interferon-gamma (IFN-γ) is known to enhance the immunosuppressive properties of MSC. IFN-γ preactivated MSC (MSC-γ) directly or indirectly modulates T cell responses by enhancing or inducing MSC inhibitory factors. These factors are known to downregulate T cell activation, enhance T cell negative signalling, alter T cells from a proinflammatory to an anti-inflammatory phenotype, interact with antigen-presenting cells and increase or induce regulatory cells. Highly immunosuppressive MSC-γ with increased migratory and reparative capacities may aid tissue repair, prolong allograft survival and induce allotransplant tolerance in experimental models. Nevertheless, there are contradictory in vivo observations related to allogeneic MSC-γ therapy. Many studies report that allogeneic MSC are immunogenic due to their inherent expression of major histocompatibility (MHC) molecules. Enhanced expression of MHC in allogeneic MSC-γ may increase their immunogenicity and this can negatively impact allograft survival. Therefore, strategies to reduce MSC-γ immunogenicity would facilitate "off-the-shelf" MSC therapy to efficiently inhibit alloimmune rejection and promote tissue repair in allotransplantation. In this review, we examine the potential benefits of MSC therapy in the context of allotransplantation. We also discuss the use of autologous and allogeneic MSC and the issues associated with their immunogenicity in vivo, with particular focus on the use of enhanced MSC-γ cellular therapy.

KW - Allogeneic

KW - Allograft rejection

KW - Allotransplantation

KW - Autologous

KW - Cellular therapy

KW - Clinical trials

KW - Immunogenicity

KW - Immunosuppression

KW - Immunosuppressive drugs

KW - Interferon-gamma

KW - Mesenchymal stem cells

KW - Modification

KW - Monotherapy

KW - Preactivation

KW - Regeneration

KW - T cells

UR - http://www.scopus.com/inward/record.url?scp=84899935769&partnerID=8YFLogxK

U2 - 10.1007/s12015-014-9495-2

DO - 10.1007/s12015-014-9495-2

M3 - Article

VL - 10

SP - 351

EP - 375

JO - Stem Cell Reviews and Reports

JF - Stem Cell Reviews and Reports

SN - 1550-8943

IS - 3

ER -